Literature DB >> 23939902

Nucleic acid polymers inhibit duck hepatitis B virus infection in vitro.

Faseeha Noordeen1, Andrew Vaillant, Allison R Jilbert.   

Abstract

Nucleic acid polymers (NAPs) utilize the sequence-independent properties of phosphorothioate oligonucleotides (PS-ONs) to target protein interactions involved in viral replication. NAPs are broadly active against a diverse range of enveloped viruses that use type I entry mechanisms. The antiviral activity of NAPs against hepatitis B virus (HBV) infection was assessed in vitro in duck hepatitis B virus (DHBV)-infected primary duck hepatocytes (PDH). NAPs efficiently entered PDH in the absence of any transfection agent and displayed antiviral activity at concentrations of 0.01 to 10 μM, measured by their ability to prevent the intracellular accumulation of DHBV surface antigen, which was independent of their nucleotide sequence and was specifically dependent on phosphorothioation. Higher levels of antiviral activity were observed with NAPs 40 nucleotides in length or longer. The fully degenerate NAP (REP 2006) was active during DHBV infection or when added 12 h after infection. In contrast, an acidic-pH-sensitive NAP (REP 2031) that was broadly active against other viruses displayed antiviral activity when present during DHBV infection but no activity when added 12 h after infection, suggesting that NAPs exert their postentry effect in an acidic environment unique to DHBV infection. Both REP 2006 and REP 2031 displayed negligible cytotoxicity in PDH at concentrations of up to 10 μM, as assessed using an XTT [2,3-bis-(2-methoxy-4-nitro-5-sulfophenyl)-2H-tetrazolium-5-carboxanilide] cytotoxicity assay. The antiviral activity of NAPs against DHBV in vitro was strictly dependent on their amphipathic character, suggesting that NAPs interact with amphipathic target(s) that are important for DHBV entry and postentry mechanisms required for infection.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23939902      PMCID: PMC3811297          DOI: 10.1128/AAC.01003-13

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  32 in total

1.  pH-independent entry and sequential endosomal sorting are major determinants of hepadnaviral infection in primary hepatocytes.

Authors:  Anneke Funk; Mouna Mhamdi; Heinz Hohenberg; Hans Will; Hueseyin Sirma
Journal:  Hepatology       Date:  2006-09       Impact factor: 17.425

Review 2.  Duck hepatitis B virus: an invaluable model system for HBV infection.

Authors:  Ursula Schultz; Elizabeth Grgacic; Michael Nassal
Journal:  Adv Virus Res       Date:  2004       Impact factor: 9.937

3.  Spectroscopic evidence for the formation of four-stranded solution structure of oligodeoxycytidine phosphorothioate.

Authors:  H Kanehara; M Mizuguchi; K Tajima; K Kanaori; K Makino
Journal:  Biochemistry       Date:  1997-02-18       Impact factor: 3.162

4.  Phosphorothioate oligonucleotides inhibit human immunodeficiency virus type 1 fusion by blocking gp41 core formation.

Authors:  Andrew Vaillant; Jean-Marc Juteau; Hong Lu; Shuwen Liu; Carol Lackman-Smith; Roger Ptak; Shibo Jiang
Journal:  Antimicrob Agents Chemother       Date:  2006-04       Impact factor: 5.191

Review 5.  Review article: Nucleoside analogues for the treatment of chronic hepatitis B.

Authors:  H M Younger; A J Bathgate; P C Hayes
Journal:  Aliment Pharmacol Ther       Date:  2004-12       Impact factor: 8.171

Review 6.  Treatment of chronic hepatitis B.

Authors:  P Marcellin; T Asselah; N Boyer
Journal:  J Viral Hepat       Date:  2005-07       Impact factor: 3.728

7.  Kinetics of duck hepatitis B virus infection following low dose virus inoculation: one virus DNA genome is infectious in neonatal ducks.

Authors:  A R Jilbert; D S Miller; C A Scougall; H Turnbull; C J Burrell
Journal:  Virology       Date:  1996-12-15       Impact factor: 3.616

Review 8.  Epidemiology and natural history of hepatitis B.

Authors:  Brian J McMahon
Journal:  Semin Liver Dis       Date:  2005       Impact factor: 6.115

9.  Potent antiscrapie activities of degenerate phosphorothioate oligonucleotides.

Authors:  David A Kocisko; Andrew Vaillant; Kil Sun Lee; Kevin M Arnold; Nadine Bertholet; Richard E Race; Emily A Olsen; Jean-Marc Juteau; Byron Caughey
Journal:  Antimicrob Agents Chemother       Date:  2006-03       Impact factor: 5.191

10.  Role of glycosaminoglycans for binding and infection of hepatitis B virus.

Authors:  Corinna M Leistner; Stefanie Gruen-Bernhard; Dieter Glebe
Journal:  Cell Microbiol       Date:  2008-01       Impact factor: 3.715

View more
  24 in total

Review 1.  Future therapy for hepatitis B virus infection.

Authors:  Masahito Minami
Journal:  Clin J Gastroenterol       Date:  2015-08-12

Review 2.  HBV/HDV Coinfection: A Challenge for Therapeutics.

Authors:  Christopher Koh; Ben L Da; Jeffrey S Glenn
Journal:  Clin Liver Dis       Date:  2019-05-24       Impact factor: 6.126

3.  Nucleic acid-based polymers effective against hepatitis B Virus infection in patients don't harbor immunostimulatory properties in primary isolated liver cells.

Authors:  Catherine Isabell Real; Melanie Werner; Andreas Paul; Guido Gerken; Joerg Friedrich Schlaak; Andrew Vaillant; Ruth Broering
Journal:  Sci Rep       Date:  2017-03-08       Impact factor: 4.379

4.  New horizon for radical cure of chronic hepatitis B virus infection.

Authors:  Kazuto Tajiri; Yukihiro Shimizu
Journal:  World J Hepatol       Date:  2016-07-28

5.  Activity of nucleic acid polymers in rodent models of HBV infection.

Authors:  Katrin Schöneweis; Neil Motter; Pia L Roppert; Mengji Lu; Baoju Wang; Ingo Roehl; Dieter Glebe; Dongliang Yang; John D Morrey; Michael Roggendorf; Andrew Vaillant
Journal:  Antiviral Res       Date:  2017-11-08       Impact factor: 5.970

Review 6.  Hepatitis B virus infection: An insight into infection outcomes and recent treatment options.

Authors:  Faseeha Noordeen
Journal:  Virusdisease       Date:  2015-04-05

Review 7.  Treatment of hepatitis B virus: an update.

Authors:  Haley Ward; Lydia Tang; Bhawna Poonia; Shyam Kottilil
Journal:  Future Microbiol       Date:  2016-11-18       Impact factor: 3.165

Review 8.  Chronic hepatitis B: A wave of new therapies on the horizon.

Authors:  Timothy M Block; Siddhartha Rawat; Carol L Brosgart
Journal:  Antiviral Res       Date:  2015-06-22       Impact factor: 5.970

9.  Nucleic Acid Polymers Are Active against Hepatitis Delta Virus Infection In Vitro.

Authors:  Frauke Beilstein; Matthieu Blanchet; Andrew Vaillant; Camille Sureau
Journal:  J Virol       Date:  2018-01-30       Impact factor: 5.103

10.  Oligonucleotides designed to inhibit TLR9 block Herpes simplex virus type 1 infection at multiple steps.

Authors:  Monica M Sauter; Joshua J L Gauger; Curtis R Brandt
Journal:  Antiviral Res       Date:  2014-07-01       Impact factor: 5.970

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.